Spyre Therapeutics (SYRE) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$36.2M

Net income growth (year over year)

+1.41%

Net margin

—

Return on equity

−22.98%

EPS (trailing twelve months)

−$1.98

Book value per share

$10.84

P/E (trailing twelve months)

—

Price to book

7.19

Debt to assets

6.13%

Payout ratio

—

Dividend yield

—

Company profile

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

• How do I buy stock in Spyre Therapeutics (SYRE)?

  SYRE trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.